Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Curis And Autolus Rise On EHA Abstract Data

Potential Advances In AML and NHL

Executive Summary

Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.

You may also be interested in...



Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME

Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.

NIH Study Keeps Synairgen’s Dream Of An Inhaled COVID-19 Therapy Alive

SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.

Leucid Bio Unveils ‘Parallel CAR-T’ Platform Targeting Solid Tumors

The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel